Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanostart-owned MagForce Nanotechnologies AG: Application submitted for EU regulatory approval of Nano-Cancer® therapy

Abstract:
* European regulatory approval expected by end of May 2010
* Sales and marketing launch now in planning
* Renowned nanomedicine expert calls it "a real medical revolution"

Nanostart-owned MagForce Nanotechnologies AG: Application submitted for EU regulatory approval of Nano-Cancer® therapy

Frankfurt / Berlin | Posted on December 1st, 2009

MagForce Nanotechnologies AG, the Berlin-based medical nanotechnology company majority-owned by Nanostart AG, has submitted its application for the European regulatory approval of its Nano-Cancer® therapy.

The application is based on the successful results of recent clinical trials involving patients with recurrent glioblastoma, an especially aggressive form of brain tumor. The results of this efficacy study demonstrated that, by using Nano-Cancer® therapy accompanied by radiation therapy, the median survival time of patients following the first recurrence of glioblastoma could be more than doubled, from 6.2 months to 13.4 months, which is seen as a breakthrough in medical terms.

The product file for approval, consisting of some 20 volumes, has now been submitted to Medcert GmbH, the designated authority for the testing and certification of medical products. The management of MagForce anticipates that the testing procedure will take three to six months and thus should be completed by the end of May. Following successful completion, the company will be able to market its proprietary Nano-Cancer® therapy throughout the European Union.

In order to make the current testing and certification process as seamless as possible, MagForce worked closely with Medcert to proactively coordinate the methodology and procedures for its clinical trials.

In parallel with the procedure for European regulatory approval, MagForce is moving forward with preparations for its market launch. These include discussions with medical insurers on cost coverage for the therapy, with potential sales partners such as major medical technology corporations, and with cancer clinics. The company's own sales and marketing organization is also being built up.

Dr. Andreas Jordan, founder and chief scientific officer of MagForce Nanotechnologies, commented, "After more than twenty years of research and development efforts, we now stand on the brink of regulatory approval. Ultimately, we aim to use our Nano-Cancer® therapy to treat all kinds of solid tumors."

Nanostart CEO Marco Beckmann added, "Nano-Cancer® therapy is quickly moving toward market launch, and its market potential is enormous. We're particularly pleased about the growing interest within the medical world in this completely new approach to cancer treatment."

Professor Mauro Ferrari, the internationally recognized expert in the area of nanomedicine, praised the latest successes at MagForce: "I would like to congratulate and thank Dr. Jordan and his team at MagForce Nanotechnologies for their outstanding contribution to nanomedicine and cancer research. What MagForce could demonstrate with the study results is historical, nothing less than a real medical revolution: The physics-based, nanoparticle-enabled therapy is highly effective and it comes with minimal side effects for the patients - you simply can't overestimate the importance of MagForce's pioneering work. It is groundbreaking, for its own importance for extended survival of brain cancer patients, and perhaps even more in terms of broader implications for future thermal ablation therapies of other types of cancer."

Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the "Entry Standard" segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan.

####

About Nanostart
Nanostart AG is the world’s leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector.

About MagForce Nanotechnologies

MagForce Nanotechnologies AG is the world’s leading company in the area of nanotechnology-based cancer treatment. Its patented therapy allows the targeted destruction of tumors using magnetic nanoparticles. MagForce’s nanotechnology represents a revolutionary approach to the future successful treatment of solid tumors. For more information, please visit www.magforce.com.

For more information, please click here

Contacts:
Media contact:
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
D-60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122

Copyright © Nanostart

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Exotic insulator may hold clue to key mystery of modern physics: Johns Hopkins-led research shows material living between classical and quantum worlds December 8th, 2016

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Journal Nanotechnology Progress International (JONPI), newest edition out December 7th, 2016

Govt.-Legislation/Regulation/Funding/Policy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Exotic insulator may hold clue to key mystery of modern physics: Johns Hopkins-led research shows material living between classical and quantum worlds December 8th, 2016

Physicists decipher electronic properties of materials in work that may change transistors December 6th, 2016

Construction of practical quantum computers radically simplified: Scientists invent ground-breaking new method that puts quantum computers within reach December 5th, 2016

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Announcements

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Exotic insulator may hold clue to key mystery of modern physics: Johns Hopkins-led research shows material living between classical and quantum worlds December 8th, 2016

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Journal Nanotechnology Progress International (JONPI), newest edition out December 7th, 2016

Nanobiotechnology

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

Alliances/Trade associations/Partnerships/Distributorships

Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016

Leti and Grenoble Partners Demonstrate World’s 1st Qubit Device Fabricated in CMOS Process: Paper by Leti, Inac and University of Grenoble Alpes Published in Nature Communications November 28th, 2016

Mechanism for sodium storage in 2-D material: Tin selenide is an effective host for storing sodium ions, making it a promising material for sodium ion batteries October 27th, 2016

Enterprise In Space Partners with Sketchfab and 3D Hubs for NewSpace Education October 13th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project